Drug Profile
Modafinil - Teva Pharmaceutical Industries
Alternative Names: AFT-801; Alertec; Attenace™; CN 801; CRL 40476; Modasamil; Modasonil; Modavigil; Modiodal; Provigil; Sparlon; VigilLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cephalon
- Developer Alfresa Pharma Corporation; Lundbeck A/S; Mitsubishi Tanabe Pharma Corporation; Teva Pharmaceutical Industries
- Class Benzhydryl compounds; Sleep disorder therapies; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypersomnia; Narcolepsy
- No development reported Alzheimer's disease
- Discontinued Attention-deficit hyperactivity disorder; Parkinson's disease
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 02 Feb 2017 Alfresa Pharma Corporation completes in a long-term phase III trial for Hypersomnia in Japan before February 2017 (JapicCTI-142615)
- 02 Feb 2017 Alfresa Pharma Corporation initiates enrolment in a long-term phase III trial for Hypersomnia in Japan before February 2017 (JapicCTI-142615)